Seeking Alpha

Gilead's (GILD) tenofovir alafenamide fumarate (TAF) treatment for HIV-1 met its primary...

Gilead's (GILD) tenofovir alafenamide fumarate (TAF) treatment for HIV-1 met its primary objective in a Phase II trial in which, in combination with other drugs, it went up against Stribild, also from Gilead. With TAF achieving a similar virological response to Stribild, the company now plans to undertake further studies. (PR)
Comments (1)
  • ambrjak
    , contributor
    Comments (3) | Send Message
     
    According to scuttle butt GILD is currently properly priced. Not taken into account is the fact that Co. is expecting their HEP-3 pill is itself forecast to generate 9B pr.annum in coming years beginning several yrs. hence. Considering the 14 current sales and pipeline products,
    and that the stock is correctly priced ,makes for a rather rosy future for this well run org. The election may make for a different view sometime in the near future.
    6 Nov 2012, 02:10 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|